首页> 外文期刊>Nanotechnology >Synthesis and characterization of pH-sensitive drinkable nanoparticles for oral delivery of ibuprofen
【24h】

Synthesis and characterization of pH-sensitive drinkable nanoparticles for oral delivery of ibuprofen

机译:对Ph敏饮料纳米粒子进行口服递送的PH敏饮料纳米粒子的合成与表征

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Ibuprofen (IBU) is a widespread drug used to treat both acute and chronic disorders. It is generally taken orally but the free drug can induce the irritation of the gastric mucosa due to its acid nature. In literature, different approaches have been adopted to prevent the release in the stomach, such as physical entrapment with film-coated tablets and drug-conjugates. Nevertheless, these solutions have many disadvantages, including the fast release of the drug and the difficulty to swallow the tablet, especially for children who may vomit or refuse the tablet. For this reason, in this work, novel formulations are proposed that do not require the encapsulation of the drug into a solid form and, in turn, their assumption as a pill. IBU has been linked to different types of methacrylates via ester bond in order to produce pH-responsive macromolecular monomers. The novelty is related to the use of these drug-conjugates macromonomer for the production of nanoparticles (NPs) via emulsion polymerization (EP), using water as solvent. The final emulsion is able to load up to 30 mg ml(-1) of IBU, so less than 10 ml is required to be assumed to reach the minimum therapeutic dose of the drug (200 mg). Finally, the release of IBU from these novel drinkable formulations has been investigated in the gastric and intestinal simulated fluids to show the preferential release of IBU from the NPs in basic conditions. A comparison with an existing oral suspension has been performed to highlight the slower release in acid environment of these new formulations. Afterwards, the IBU loaded NPs were tested in vitro showing lower toxicity compared to the free drug.
机译:布洛芬(IBU)是一种用于治疗急性和慢性病的广泛药物。它通常是口服的,但由于其酸性,自由药物可以诱导胃粘膜的刺激​​。在文献中,已经采用了不同的方法来防止胃中的释放,例如用薄膜涂覆的片剂和药物缀合物的物理夹带。然而,这些解决方案具有许多缺点,包括药物的快速释放和难以吞下平板电脑,特别是对于可能呕吐或拒绝平板电脑的儿童。因此,在这项工作中,提出了一种不需要将药物封装成固体形式的新制剂,并且反过来它们作为丸剂的假设。 IBU通过酯键与不同类型的甲基丙烯酸酯连接以产生pH-响应的大分子单体。新颖性与使用这些药物 - 缀合物Macromomer用于通过乳液聚合(EP)的生产纳米颗粒(NPS),用水作为溶剂。最终乳液能够负载高达30mg mL(-1)的IBU,因此需要少于10mL达到药物的最小治疗剂量(200mg)。最后,在胃肠和肠模拟流体中研究了来自这些新型饮用制剂的IBU的释放,以显示来自NPS的基本条件中的IBU的优先释放。已经进行了与现有的口腔悬浮液的比较以突出这些新配方的酸环境中的较慢释放。之后,与游离药物相比,在体外测试IBU载荷的NPS,显示出较低的毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号